NCT05248659View on ClinicalTrials.gov

Phase 2/3 Open-Label Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy

PHASE2/PHASE3Enrolling by invitationINTERVENTIONAL
Enrollment

600

Participants

Timeline

Start Date

April 5, 2022

Primary Completion Date

December 28, 2028

Study Completion Date

December 28, 2028

Conditions
Immunoglobulin A Nephropathy
Interventions
DRUG

Sibeprenlimab 400 mg s.c. Q4weeks

Sibeprenlimab 400 mg s.c. q 4 weeks

Trial Locations (1)

10001

For additional information regarding sites, contact 844-687-8522, New York

All Listed Sponsors
lead

Otsuka Pharmaceutical Development & Commercialization, Inc.

INDUSTRY